TD Cowen Maintains Buy on AstraZeneca, Raises Price Target to $95
Portfolio Pulse from Benzinga Newsdesk
TD Cowen analyst Steve Scala maintains a Buy rating on AstraZeneca (NASDAQ:AZN) and raises the price target from $90 to $95.
August 12, 2024 | 2:59 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
TD Cowen analyst Steve Scala maintains a Buy rating on AstraZeneca and raises the price target from $90 to $95.
The raised price target and maintained Buy rating from a reputable analyst can positively influence investor sentiment and potentially drive the stock price higher in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100